Viking Therapeutics, Inc. (NASDAQ: VKTX) jumps over 4% in pre trading session on Wednesday as the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of VK2735 that the business conducted has shown encouraging findings, according to the company. The substance is a new dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors that is being researched as a potential therapy for a variety of metabolic problems. The business intends to start a Phase 2 investigation of VK2735 in individuals...